

Resource Summary Report

Generated by PRECISE-TBI on Aug 9, 2026

CD20

RRID:AB_395989

Type: Antibody

Proper Citation

BD Biosciences Cat# 555623, RRID:AB_395989

Antibody Information

URL: http://antibodyregistry.org/AB_395989

Proper Citation: BD Biosciences Cat# 555623, RRID:AB_395989

Target Antigen: CD20

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow cytometry, Immunohistochemistry

Antibody Name: CD20

Description: This monoclonal targets CD20

Target Organism: baboon, cynomolgus, rhesus, human

Antibody ID: AB_395989

Vendor: BD Biosciences

Catalog Number: 555623

Record Creation Time: 20250820T043018+0000

Record Last Update: 20250820T190857+0000

Ratings and Alerts

No rating or validation information has been found for CD20.

No alerts have been found for CD20.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Karaliota S, et al. (2025) Highly immunogenic DNA/LION nanocarrier vaccine potently activates lymph nodes inducing long-lasting immunity in macaques. iScience, 28(4), 112232.

Champiat S, et al. (2025) Nanrilkefusp alfa (SOT101), an IL-15 receptor ?? superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers. Cell reports. Medicine, 6(2), 101967.

Demirci S, et al. (2024) BCL11A +58/+55 enhancer-editing facilitates HSPC engraftment and HbF induction in rhesus macaques conditioned with a CD45 antibody-drug conjugate. Cell stem cell.

Demaria O, et al. (2022) Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant. Cell reports. Medicine, 3(10), 100783.

Zhu Y, et al. (2019) Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer. Cell stem cell, 25(4), 542.

Li D, et al. (2019) Evaluation and use of an anti-cynomolgus monkey CD79b surrogate antibody-drug conjugate to enable clinical development of polatuzumab vedotin. British journal of pharmacology, 176(19), 3805.